SUPPLEMENTAL DATA
A ANOVA analysis and used to train the different algorithms (see Table S4 ). 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Isolation of platelet RNA and plasma DNA and assessment of platelet purity
Platelets and plasma were isolated from whole blood collected prospectively in purple-cap BD Vacutainers containing EDTA anti-coagulant by standard centrifugation as described previously (Nilsson et al., 2011) . The cells and aggregates were removed by centrifugation at room temperature for 20 min at 120g, resulting in platelet-rich plasma. The platelets were isolated from the platelet-rich plasma by centrifugation at room temperature for 20 min at 360g, after which the plasma was centrifuged at 5000 rpm for 10 min and frozen. The platelet pellet was collected in 30 µl RNAlater (Life Technologies), incubated overnight at 4°C and frozen at -80°C for further use. Plasma was stored directly at -80°C. To assess sample purity, seven freshly isolated and randomly selected platelet isolations in RNAlater were fixed in 3.7% paraformaldehyde and stained by Crystal-Violet staining (ratio 1:1). Total platelet and nucleated cell counts was determined by manual cell counting in 7 µl cell counting chambers on an light microscope by two observers (M.G.B. and T.W.) and yielded an estimated 1 to 5 nucleated cell counts per 10 million platelets, which is in concordance to observations by others (Rolf, 2005) .
Plasma DNA was isolated using the QiaAmp DNA Blood Mini Kit (Qiagen). The plasma DNA concentration and quality was determined using the Bioanalyzer 2100
with DNA High Sensitivity chip (Agilent). Plasma DNA was stored at -20°C for amplicon sequencing. Frozen platelets were thawed on ice and total RNA was isolated using the mirVana RNA isolation kit (Life Technologies) according to the manufacturers' protocol. Complementary purification of small RNAs was included in the isolation procedure by addition of miRNA homogenate (Life Technologies). Total RNA was dissolved in 30 µl Elution Buffer (Life Technologies) and RNA quality and quantity was measured using the RNA 6000 Picochip (Agilent).
Platelet mRNA sequencing
Platelet total RNA (Bioanalyzer RIN values > 7 and/or distinctive rRNA curves) was subjected to cDNA synthesis and amplification using the SMARTer Ultra 
Differential expression of transcripts
Prior to computation of differentially expressed transcripts ('ANOVA testing for differences'), genes with less than five (non-normalized) read counts in all samples were excluded from analyses. Next, data normalization factors were calculated that are incorporated in further analyses by the weighted trimmed mean of M-values ("TMM") method (Robinson and Oshlack, 2010) . After fitting of negative binominal models and both common, tagwise and trended dispersion estimates were obtained, differentially expressed transcripts were determined using a generalized linear model (GLM) likelihood ratio test (McCarthy et al., 2012) . To minimize the effect of batch effect, resulting in possibly false positive results, 'sequencing batch' was included as a covariate in the GLM likelihood ratio test design matrix. All steps are implemented in the R-package edgeR (version 3.8.5) . To determine differentially expressed transcripts, we only focused on transcripts with expression levels of logarithmic counts per million (LogCPM) > 3. Genes located on the Ychromosome were omitted from all analyses, except from the gender-clustering analysis, to exclude the effect of gender-specific mRNAs. Unsupervised hierarchical clustering was performed by Ward clustering and Pearson distances. Non-random partitioning, and corresponding p value, of unsupervised hierarchical clustering was determined using a Fisher's exact test.
Correlation matrices
The correlation of mRNA sequencing data from healthy donors and TEPs was determined using the mean counts per million (CPM)-normalized Log 2 -transformed read counts per condition (healthy donors, TEPs). Pearson correlation coefficient was calculated by the 'cor'-function in R (package 'stats'). Red and blue dots, representing significantly increased and decreased transcripts, respectively, as determined by differential expression calculations, were superimposed on the graph.
Pearson correlation coefficient of the sequenced platelet RNA samples with profiles of purified platelets, bone marrow megakaryocytes and circulating immune cells was determined using publicly available datasets. mRNA sequencing data of two, four, and four healthy donor platelet preparations, respectively, were obtained from Table S2A ) (Bray et al., 2013) , and Kissopoulou et al. (Supplemental Table 3 ) (Kissopoulou et al., 2013) . The latter dataset was subdivided in a sample prepared using SMARTScribe Oligo-dT-primed cDNA synthesis and amplification (Sample S0), and ribosomal RNA depleted preparation (Sample S1-3) (Kissopoulou et al., 2013) . chip. After pooling of the library the standard Illumina protocol for the MiSeq sequencer was followed. The loading molarity was 6 pM or 9 pM, and the PhiX spikein was 50% for every run. The runs were 2x150 cycles paired-end using the version 2 Reagent Kit system. Raw reads were trimmed and quality control was performed.
Reads were mapped to the human reference genome (hg19) by Bowtie (v.1.1.2) while permitting three mismatches in the 70 nt seed region, unmapped reads were removed, and single nucleotide mutant variants were selected. Samples with less than 100,000 total read counts were excluded from analyses (i.e 4 out of 98 sequenced plasma samples and 11 out of 152 sequenced TEP samples). Detected variants compared to the reference wild-type code included codon 12 (G12A, G12C, G12D, G12R, G12S and G12V) and codon 13 (G13D, G13C) of exon 2 of KRAS and exon 20 (T790M) and exon 21 (L858R and R861Q) of EGFR. Read counts were normalized for total number of reads per sample and corrected for intra-experimental variation. Per mutational variant, robust z-scores using the mean absolute deviation (MAD; robust Z = (x -m) / (1.4825 * MAD), in which x is the score of a sample and m is the median of the healthy donor cohort) were calculated and detected variants with a robust z-score of more than four standard deviations above the mean z-score of the healthy donor cohort were scored as positive. Furthermore, to take the error rate of the Phusion HF PCR enzymes into account, the ratio of specific mutant variant reads per wild-type reads had to exceed 1/5,000. Also, 'hypermutant' samples, defined as more than three mutant variants in KRAS, were excluded from analysis (i.e. 1 out of 235 analyzed samples). A cohort of 30 (KRAS) and 21 (EGFR) healthy donors plasma DNA and platelet RNA served as a control population and were included in the reported data as KRAS or EGFR wild-type individuals. Kappa statistics (Cohen's kappa coefficient for interrater agreement) and corresponding 95% confidence intervals were used to determine tissue-concordance.
